Our findings indicated that targeting ACSL4 or, alternatively, upregulating GPX4 or FSP1 may help mitigate AKI by reducing ferroptosis, offering potential therapeutic strategies for oxalate-induced AKI. Here, GPX4 is linked to acute kidney injury.